Characterising the motif composition and allele length distribution of *ZFHX3* GGC repeat expansions in amyotrophic lateral sclerosis

Zoe N. Zussa[1], Andrew N. Smith[1], Joke J.F.A van Vugt[2], Daniel S. O'Shaughnessy[1], Natalie Grima[1], Sandrine Chan Moi Fat[1], Ian P. Blair[1], Dominic B Rowe[1, 3], Roger Pamphlett [4], Garth A. Nicholson[5, 6], Matthew C.K Kiernan[7], Wouter van Rheenen[2], Jan Veldink[2], Project MinE ALS sequencing consortium, Kelly L. Williams[1*] and Lyndal Henden[1*+]

[1] Macquarie University Motor Neuron Disease Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia

[2] Department of Neurology, UMC Utrecht Brain Center, Utrecht University, 3584 CX Utrecht, The Netherlands

[3] Macquarie University Health Neurology, Macquarie University, Sydney, NSW, Australia

[4] Department of Neuropathology, The University of Sydney, Sydney, NSW, Australia

[5] Molecular Medicine Laboratory, Concord Repatriation General Hospital, Sydney, NSW 2139, Australia

[6] Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, NSW 2139, Australia

[7] Neuroscience Research Australia, and the University of NSW, Sydney, NSW, Australia

[*] Contributed equally to this work

[+] Corresponding author: lyndal.henden@mq.edu.au

Abstract

Background and objectives: A pathogenic GGC repeat expansion in the zinc finger
homeobox 3 (*ZFHX3*) gene, encoding a pure polyglycine tract, is the cause of
spinocerebellar ataxia type 4 (SCA4). Intermediate expansions of other SCA loci
contribute to the risk of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative
disease involving the progressive loss of motor neurons. There is increasing awareness
of the role of short tandem repeat (STR) motif composition and configuration in disease
pathogenicity. Given the genetic pleiotropy between ALS and SCA, this study aimed to
evaluate whether *ZFHX3* GGC expansions were associated with ALS and to characterise
repeat motif composition.

Methods: ExpansionHunter v5 was used to genotype *ZFHX3* GGC repeat sizes in short-
read whole genome sequencing data from people with ALS and healthy controls of
European ancestry. Repeat sizes were visually inspected using REViewer v2. Repeat
motif configurations of Australian ALS cases and healthy controls were manually derived
from REViewer images. Receiver operating characteristic (ROC) curve analysis and
Youden's J statistic were performed to find a candidate repeat size threshold for
association testing. Fisher's exact tests were performed to evaluate the associations of
repeat size and motif composition with disease status.

Results: Analysis of 5,785 people with ALS and 7,982 healthy controls found no
association between *ZFHX3* GGC repeat expansions and disease risk. Fifty unique
repeat motif compositions were identified across 802 people with ALS and 800 healthy
controls. Of these, eleven distinct configurations coded a pure polyglycine tract which,
when expanded, is canonical to SCA4, though no association with ALS was found.

Discussion: Although no association was observed between *ZFHX3* GGC repeat
expansions and ALS, this study established the dynamic nature of *ZFHX3* repeat motif
composition and configuration. Unique motif compositions were identified both within and
between repeat sizes, including the presence of pure polyglycine repeats. Consideration
of repeat motif composition and configuration, in addition to repeat allele length, may be
important for assessing neurodegenerative disease risk.

Introduction

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterised by progressive degeneration of upper and lower motor neurons, resulting in muscle weakness, paralysis and death, typically due to respiratory failure within 3-5 years of symptom onset[1]. Gene mutations are the only proven cause of ALS, accounting for two-thirds of familial (inherited) ALS cases and ~20% of sporadic ALS cases[2]. ALS appears genetically heterogenous, with more than 30 genes and over 1,000 genetic variants implicated in disease risk or causality to date[3]. The most common genetic cause of ALS is a pathogenic short tandem repeat (STR) expansion in the intron of the *C9orf72* gene which accounts for disease in 40% of familial and 10% of sporadic cases[1]. The genetic landscape of ALS is further complicated by pleiotropy where the same mutation can give rise to different phenotypes and different disease manifestations. Notably the *C9orf72* repeat expansion is also the most common genetic cause of frontotemporal dementia (FTD); a neurodegenerative disease characterised by behavioural and cognitive decline[4]. Pleiotropy in ALS extends beyond *C9orf72*, with increasing genetic evidence linking ALS and spinocerebellar ataxia (SCA); a group of neurodegenerative disorders marked by progressive loss of balance, coordination and slurred speech[5]. Pathogenic CAG repeat expansions in *ATXN1* and *ATXN2* cause SCA1 and SCA2, respectively, while intermediate-length CAG expansions in these genes have been associated with increased ALS risk[6,7,8].

Recently, a coding pathogenic GGC repeat expansion in exon 10 of the zinc finger homeobox 3 gene (*ZFHX3*) was identified as the cause of SCA4 in families with Northern European ancestry, placing SCA4 among the growing group of polyglycine (polyG) expansion disorders[9,10,11]. *ZFHX3* encodes a transcription factor for neuronal and myogenic cell differentiation and cell proliferation[12]. Pure polyG repeat expansions in *ZFHX3* exceeding 41 GGC repeats lead to a pathogenic gain of gene function resulting in neuron degeneration, which is a hallmark pathological feature of both SCA and ALS[9]. Interestingly, individuals with SCA4 also show loss of motor neurons in the anterior horns and degradation of posterior tracts of the spinal cord, consistent with ALS pathology[10].

Investigations of STRs in polyG disorders and SCAs have emphasised the importance of motif composition (i.e. the exact sequence of nucleotides or amino acids in the expanded repeat) given that the presence and configuration of synonymous or missense

interrupting motifs can modify disease phenotype and clinical presentation[13,14,15].
Synonymous interruptions are nucleotide changes that alter repeat motif composition
without changing the encoded amino acid and have been demonstrated to occur in polyG
and polyglutamine (polyQ) disorders. For example, glycine GGC expansions in the
NOTCH2NLC gene cause neuronal intranuclear inclusion disease (NIID). NIID individuals
with the muscle weakness phenotype carried multiple glycine GGA synonymous
interruptions, whereas NIID individuals with the parkinsonism-dominant phenotype
carried fewer GGA motifs and more AGC (serine) missense interruptions[16]. Additionally,
intermediate-sized glutamine CAG expansions in *ATXN2* that specifically confer risk for
Parkinson's disease, Lewy body dementia and ALS, contain glutamine GAA synonymous
interruptions that alter repeat motif composition without changing the encoded amino
acid[17,18]. Interruptions in repeat sequences are primarily recognised for their protective
role in maintaining genomic stability by preventing slippage during DNA replication and
repair[19]. Beyond this canonical function, interruptions may also modulate variability in
disease phenotype and clinical presentation, although the exact mechanism driving these
effects remain unclear. This highlights the importance of assessing motif composition and
configuration when examining association of STR expansions with disease. Given the
phenotypic overlap and genetic pleiotropy between SCA and ALS and increasing
awareness of the importance of motif compositions in STRs, we aimed to evaluate
whether *ZFHX3* GGC repeat expansions are associated with ALS and characterise the
motif composition and configuration in a large ALS and control cohort of European
ancestry.

Methods

<u>Standard protocol approvals, registrations and patient consents</u>

This study was approved by the human research ethics committees of Macquarie
University (ID: 10134) and by the institutional review boards of all participating centres
within Project MinE. Written informed consent was provided from all participants for
investigation and publication at their respective centres and additional approval was
obtained from the Medical Ethical Testing Committee NedMec and the Biobanks Testing
committee of UMC Utrecht. Patients were included irrespective of their carrier status for
variants in known ALS-associated genes.

<u>International ALS cohort and control participants</u>

A total of 6,114 people with ALS and 8,030 healthy controls were initially included in this

study. ALS was diagnosed by a neurologist according to the El Escorial criteria or based

on progressive weakness in the upper and lower motor neurons, confirmed

by electrophysiology of widespread muscle denervation and no other diagnosis being

found on neuroimaging[20]. The ALS cohort comprised 943 Australian participants recruited

from the Macquarie University Neurodegenerative Disease Biobank and the Australian

MND DNA Bank. The remaining 5,171 individuals with ALS were obtained from Project

MinE data freeze 2; an international ALS genomics consortium spanning 14 countries[21]

summarised in Supplementary Table 1. All individuals with ALS were genotyped for the

hexanucleotide repeat expansion in *C9orf72* and known pathogenic ALS variants

in *SOD1, TARDBP,* and *FUS.* The control cohort comprised of 1,801 healthy individuals

included in Project MinE data freeze 2 and 6,229 controls from the gnomAD European

(non-Finnish) short tandem repeat data download v3.1.2.

To retain individuals of European ancestry for this study, ALS genotype call sets for all

ALS cases and Project MinE controls were merged with the combined HapMap phase II

and III datasets consisting of 11 populations[22]. Principal component analysis was

performed using PLINK V1.9[23] to identify samples clustering with the HapMap CEU and

TSI populations, representing European ancestry. Duplicate samples were detected and

removed using PLINK v1.9. A single proband was selected from ALS families where

multiple individuals were available for analysis.

<u>*ZFHX3* GGC repeat expansion detection, validation and motif composition</u>

Whole genome sequencing (WGS) data were available for all ALS cases and Project

MinE controls of European ancestry. Details on WGS sequencing and data processing

are described in the eMethods. The *ZFHX3* GGC repeat expansion was genotyped from

GRCh38 aligned BAMS using ExpansionHunter[24] v5 with the gnomAD variant catalogue

excluding off target regions (json provided in eMethods). Individual-level

ExpansionHunter outputs were merged into a cohort callset and summarised using

TRTools[25] mergeSTR and statSTR. For each allele a quality score (Q score) was

calculated and then averaged for an individual level Q score, using the ExpansionHunter
repeat length and confidence intervals, to align with the Q score metric reported in the
gnomAD callset[26,27]. The *ZFHX3* GGC ExpansionHunter callset derived from WGS data
was then merged with the gnomAD control callset. Individuals with a Q score below 0.2
were removed, based on a threshold to optimise sensitivity and specificity[26].

73 alleles (36 cases; 37 controls) with a repeat expansion length ≥24 GGC units were
visually validated using REViewer[28] v2. 12 alleles (4 cases; 9 controls) were incorrectly
estimated by three or more repeats upon visualisation in REViewer, as these genotypes
could not be reliably corrected, they were removed from the analysis. The repeat motif
composition of all 802 Australian ALS participants and a random sample of 800 healthy
control participants was catalogued by manual visualisation of individual REViewer
images. RStudio v5.1 was used to generate repeat length distributions and motif
composition figures.

<u>Statistical analysis of patient clinical data and association testing</u>

Patient phenotypic features were extracted from clinical records and variability was
examined across sex, site of disease onset (bulbar or spinal), age at disease onset and
disease duration (from onset until death or last known date alive). All statistical analysis
was performed in RStudio v5.1. Associations between sex and site of onset were
assessed using a chi-squared test of independence. Welch's two sample t tests were
used to evaluate differences in age at disease onset by both sex and site of onset.
Kaplan-Meier survival analysis compared disease duration across both sex and site of
onset. A linear regression model was fitted to assess the relationship between age at
onset and duration for deceased patients only. Alleles with repeats lengths greater than
21 units (the median repeat length) were retained to perform a receiver operating
characteristic (ROC) curve analysis and to calculate the Youden's J statistic using the R
package, cutpointr[29]. Fisher's exact tests were used to evaluate the association of
repeats expanded ≥24 GGC units and the presence of pure polyG compositions with
disease status.

<u>Data availability</u>

Individual-level *ZFHX3* repeat allele size data for 5,785 people with ALS and 7,982
healthy controls plus individual-level motif composition data for the subset of 802
Australian cases with ALS and 800 healthy controls is available at Zenodo (DOI:
10.5281/zenodo.18931240).

Code written in R is available in R Markdown workbooks in a GitLab repository:
https://gitlab.com/mq-mnd/grp_williams/zfhx3_analysis_publication_2026.

Results

Cohort summary

After filtering the cohort for ancestry and repeat quality, 5,785 participants with ALS (802
Australian ALS; 4,983 Project MinE ALS) and 7,982 healthy controls (6,215 gnomAD
controls; 1,767 Project MinE controls) were retained for downstream analysis. Cohort
demographic and clinical features of 13,767 individuals are summarised in Table 1. The
ALS cohort comprised 61% males while 74% of controls were male. Of 5,785 people with
ALS, 430 carried a known ALS disease-causal variant (Supplementary Table 2).

Differences in site of onset (P = 2.3e-27) and age of onset (P = 3.8e-13) between male
and females were observed. 71% of males presented with spinal onset versus 59% of
females (Figure 1A). The average disease onset was 61.2 years in females and 58.7 in
males (Fig 1B). Males presented with a longer disease duration than females (Fig 1C; P =
1.9e-06). Individuals who presented with ALS at a younger age had a longer disease
duration (Fig 1D; P = 1.06e-11). 66% of people with ALS had spinal onset. People with
spinal onset had a younger age of onset (P = 2.1e-47; Fig. 1E) and slower disease
progression (P = 3.4e-31) compared to bulbar onset cases (Fig 1E and F). This is
concordant with existing published ALS cohorts[6, 30].

Frequency of *ZFHX3* GGC repeat lengths

The distribution of *ZFHX3* GGC repeat lengths across 11,270 ALS alleles and 15,964
healthy control alleles was visualised (Figure. 2). Repeat sizes ranged from 4-30 units in
people with ALS and 5-29 in healthy controls. No individuals exceeded the pathogenic
threshold of 42 GGC repeat units reported in SCA4 families (Supplementary Table 3).

ROC analysis and Youden's J statistic indicated that repeat length 24 was the optimal

threshold to test for an association between cases and controls (Supplementary Figure

1). Yet a Fisher's exact test revealed no association between expanded GGC repeats ≥24

in people with ALS compared to healthy controls $(P = 0.088)$.

<u>Variability of repeat motif compositions and configurations in *ZFHX3*</u>

The frequency of 50 distinct repeat motif compositions from 802 Australian ALS

individuals and 800 healthy controls across both alleles was visualised (Figure 3). All

repeat motif compositions were interrupted by at least one GGT (glycine) motif that

produces a synonymous interruption in the polyglycine tract. Two-thirds of these distinct

motifs (32/50) were present in a single individual. Eleven motif compositions across 21

alleles (9 cases, 12 controls) lacked a missense interruption and coded pure glycine

tracts, ranging in size from 5-26 repeat motifs. One individual with ALS carried a pure

polyglycine tract on both alleles, with repeat lengths 23 and 26. A Fisher's exact test

revealed no association between pure polyglycine tracts in people with ALS compared to

healthy controls $(P = 0.521)$. The most common motif composition (in 84.7% of ALS

alleles and 84.3% of control alleles) was present in alleles with 21 repeats, and

comprised 18 GGC (glycine) motifs, interrupted by two GGT (glycine) motifs and one AGT

(serine) motif (Figure 3 and Supplementary Figures 2 and 3). Each repeat length had

multiple configurations in their motif composition, with the exception of repeat lengths 5,

25 and 26, which each had only one configuration. Alleles with a repeat length of 19 and

23 had the greatest number of different motif compositions, each with eight distinct

configurations identified. Whereas alleles with a repeat length of 21 showed the highest

variability in interrupting motifs, with five distinct noncanonical GGC motifs observed

across six different motif compositions. Double missense interruptions occurred in 137

alleles (74 cases, 63 controls), most commonly involving combinations of AGT (serine)

and GAC (aspartic acid) motifs. A single ALS allele with an AGC motif co-occurred with

an AGT motif, resulting in a double serine interruption. A detailed breakdown of the motif

composition seen in 1,604 ALS alleles and 1,600 control alleles is provided in

Supplementary Figures 2 and 3 and Supplementary Table 4.

Discussion

A pathogenic GGC repeat expansion in *ZFHX3* was recently reported as the cause of
SCA4[9,10,11]. Given that intermediate expansions at other SCA loci, including *ATXN1* and
ATXN2, are associated with increased risk of ALS[6,7,8], and the pathological overlap of
SCA4 and ALS[10], we investigated whether *ZFHX3* GGC expansions similarly contribute
to ALS risk. Using ExpansionHunter-derived genotypes from whole-genome sequencing
data, we found no evidence of association between expanded *ZFHX3* GGC repeats and
ALS in a large European cohort, indicating that repeat length does not contribute to the
risk of ALS.

Beyond repeat size, motif composition and sequence architecture are increasingly
recognised as determinants of pathogenicity in repeat expansion disorders. In
polyglutamine (polyQ) and polyglycine (polyG) diseases, interruption pattern, motif order,
and tract purity can influence repeat instability, penetrance, and age at disease onset[14,16,]
[31, 32]. In our cohort, we identified 50 distinct *ZFHX3* repeat motif configurations among
802 individuals with ALS and 800 healthy controls. Two-thirds of these distinct
configurations were present in only one individual. All contained at least one synonymous
or missense interruption, alongside eleven compositions that encode uninterrupted polyG
tracts. In contrast, pathogenic SCA4 expansions consist of long, pure, uninterrupted
polyG tracts[9, 10]. Pure repeat tracts are thought to be more prone to replication slippage
and somatic instability, making them susceptible to further expansion[19], and conversely,
interrupted tracts may confer locus stability. In addition, the interruption pattern and motif
configuration of repeats may influence transcription and RNA processing independent of
repeat length[33]. Understanding how synonymous or missense interruptions influence and
stabilise repeat expansions may inform therapeutic strategies that aim to introduce
interruptions to stabilise pathogenic repeat tracts, a strategy currently being explored in
other repeat expansion disorders[34]. Together, our findings reinforce the importance of
resolving repeat motif configuration, not solely allele size, when assessing the
pathogenicity of expanded repeats.

This study had several limitations. Although cohort size was substantial, the analysis was
restricted to individuals of European ancestry. Since ALS is genetically heterogeneous
with mutation frequencies that vary across ancestral backgrounds[35, 36], future studies that
incorporate diverse ancestral populations will be important to more definitively evaluate
the contribution of *ZFHX3* GGC expansions and motif configurations to ALS risk. In
addition, while short-read sequencing datasets are widely available for ALS genomic

studies, short-read data has inherent limitations for STR analysis. Repeat lengths that
exceed the read length cannot be directly spanned, potentially leading to underestimation
of larger repeat sizes. GC-rich motifs can introduce coverage bias and interrupted or
structurally complex repeats may not be reliably resolved with short-read data. Indeed, a
combination of short- and long-read sequencing was required to initially characterise the
pathogenic *ZFHX3* GGC expansion in SCA4 families[9,10,37]. However, once the locus was
defined, short-read sequencing was sufficient to reidentify individuals with SCA4 and
detect previously unresolved ataxia and sensory neuropathy cases harbouring the
ZFHX3 GGC expansion[9]. Moreover, the repeat length distribution of non-disease alleles
was consistent with that observed here[9,37]. Although repeat length was evaluated in a
large number of both cases and controls, detailed motif composition was manually
characterised only in a subset of the cohort. The population frequency and broader
distribution of these configurations may require systematic assessment in more
comprehensive populations.

In conclusion, we found no evidence that expanded *ZFHX3* GGC repeats contribute to
ALS risk, and no association between pure polyG tracts and ALS in a large European
cohort. However, the marked diversity of repeat motif configurations at this locus
highlights the importance of interrogating sequence composition, not solely allele size,
when evaluating STRs in neurodegenerative disease. Future studies that integrate long-
read sequencing, diverse populations, and detailed phenotypic data will be essential to
fully define the genetic and biological relevance of *ZFHX3* repeat variation in ALS and
related disorders.

Acknowledgements

Biospecimens and related clinical data from Australian participants were obtained from
the Macquarie University Neurodegenerative Disease Biobank and the Australian MND
DNA Bank. The authors would like to acknowledge Susan D'Silva, Lorel Adams, Srestha
Mazumder and Rosie Fell for compiling and collating clinical and demographic data. The
authors would also like to gratefully acknowledge the participants who provided biological
samples for this study. The collaboration project is co-funded by the PPP Allowance made
available by Health~Holland, Top Sector Life Sciences & Health, to stimulate public-
private partnerships. This study was supported by the ALS foundation Netherlands.

Project MinE work was sponsored by NOW-Domain science for the use of supercomputer
facilities.

Author contributions

Z. N. Zussa: Draft/ revision of manuscript for content, major role in acquisition of data,
analysis or interpretation of data. A.N. Smith: major role in acquisition of data, analysis or
interpretation of data. J. J.F.A Van Vugt: major role in acquisition of data, analysis or
interpretation of data. D. S. O'Shaughnessy: interpretation of data. N. Grima: major role in
acquisition of data. S. Chan Moi Fat: interpretation of data. I. P. Blair: major role in
acquisition of data. D. B. Rowe: major role in acquisition of data. R. Pamphlett: major role
in acquisition of data. G. A. Nicholson: major role in acquisition of data. M. C. Kiernan:
major role in acquisition of data. W. V. Rheenen: major role in acquisition of data J.
Veldink: major role in acquisition of data. K. L. Williams: Draft/ revision of manuscript for
content, major role in acquisition of data, analysis or interpretation of data, study concept
or design, supervision. L. Henden: Draft/ revision of manuscript for content, major role in
acquisition of data, analysis or interpretation of data, study concept or design,
supervision.

Funding

302 MotorOn scholarship to Z. N. Zussa. FightMND and the National Health and Medical
303 Research Council of Australia (GNT2033019) fellowships to K. L. Williams. Motor Neuron
304 Disease Australia Innovator Grant to L. Henden. FightMND Angie Cunningham PhD
305 Scholarship and Project Grant-In-Aid Award to N. Grima and I. P. Blair. National Health
306 and Medical Research Council funding to M. C. Kiernan.

Disclosure

309 DBR reports consultancies or advisory boards for Biogen, Celosia Therapeutics, and
310 Genetic Signatures. JHV reports to have sponsored research agreements with Biogen,
311 Eli Lilly, Trace and Astra Zeneca.

AI statement

During the preparation of this manuscript (February 2025) the authors used ChatGPT 5.2 to improve the readability of content already written by the authors. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility of the content of the publication.

318   **Tables**

319   **Table 1. Demographic and clinical information for study cohort.**

	ALS (n = 5,785)	Controls (n = 7,982)
Sex (Males)	3,504 (61%)	4,635 (74%)
Age at disease onset (years)	59.7 ± 12.7	-
Disease duration (months)	9.80 ± 21.1	-
Site of onset		
Bulbar	1,490 (27%)	-
Spinal	3,836 (68%)	-

Age at disease onset and disease duration are presented as mean ± standard deviation. Age at onset was available for 5,563/5,785 individuals, disease duration was available for 5,445/5,785 individuals and site of onset was available for 5,612/5,785 individuals with ALS.

Figure legends

Figure 1. Statistical analysis of clinical variables in the ALS cohort (n = 5,785)

Significant associations are denoted by red *P* values. (**A**) There was a significant difference in site
of onset between males and females with ALS, as more males presented with spinal onset. **(B)**
Age at disease onset was significantly older in females with ALS. **(C)** Males with ALS have a
significantly longer disease duration than females. **(D)** Individuals diagnosed with ALS at a
younger age lived significantly longer than those diagnosed later in life. **(E)** People with bulbar
onset ALS presented with disease at an older age. **(F)** People with bulbar onset experienced a
significantly shorter disease duration than people with spinal onset.

Figure 2. Frequency of *ZFHX3* GGC repeat lengths in ALS cases and controls

ROC analysis and Youden's J statistic identified repeat length 24 as the optimal threshold for
association test, indicated by the dashed line. However, the frequency of expanded *ZFHX3* GGC
repeats ≥24 in ALS cases was not significantly increased compared to controls. The y-axis is a
log scale of percent frequency to allow better depiction of frequency variations.

Figure 3. Frequency of 50 distinct repeat motif compositions in 802 Australian ALS
cases and 800 controls

Frequency of distinct repeat motif compositions across 1,604 alleles from 802 Australian ALS
cases and 1,600 alleles from 800 healthy controls, ordered by repeat length. For each motif
composition, the first column of pie charts shows the proportional contribution of all repeat motifs,
while the second column shows motif proportions after excluding the canonical GGC repeat. An
asterisk (*) denotes a repeat motif composition lacking a missense interruption and represents a
pure glycine tract. Counts are displayed on a log scale to allow for easier depiction of frequency
variability.

References:

1.   Shatunov, A., & Al-Chalabi, A. (2021). The genetic architecture of ALS. In Neurobiology of Disease (Vol. 147). Academic Press Inc. https://doi.org/10.1016/j.nbd.2020.105156

2.   Grassano, M., Calvo, A., Moglia, C., Sbaiz, L., Brunetti, M., Barberis, M., Casale, F., Manera, U., Vasta, R., Canosa, A., D'Alfonso, S., Corrado, L., Mazzini, L., Dalgard, C., Karra, R., Chia, R., Traynor, B., & Chiò, A. (2022). Systematic evaluation of genetic mutations in ALS: a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 93(11), 1190–1193. https://doi.org/10.1136/jnnp-2022-328931

3.   McCann, E. P., Grima, N., Fifita, J. A., Chan Moi Fat, S., Lehnert, K., Henden, L., Blair, I. P., & Williams, K. L. (2023). Characterising the Genetic Landscape of Amyotrophic Lateral Sclerosis: A Catalogue and Assessment of Over 1,000 Published Genetic Variants. Journal of Neuromuscular Diseases, 10(6), 1127–1141. https://doi.org/10.3233/JND-230148

4.   Abramzon, Y. A., Fratta, P., Traynor, B. J., & Chia, R. (2020). The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. In Frontiers in Neuroscience (Vol. 14). Frontiers Media S.A. https://doi.org/10.3389/fnins.2020.00042

5.   Klockgether, T., Mariotti, C., & Paulson, H. L. (2019). Spinocerebellar ataxia. Nature Reviews Disease Primers, 5(1). https://doi.org/10.1038/s41572-019-0074-3

6.   Henden, L., Fearnley, L. G., Grima, N., Mccann, E. P., Dobson-Stone, C., Fitzpatrick, L., Friend, K., Hobson, L., Chan, S., Fat, M., Rowe, D. B., D'silva, S., Kwok, J. B., Halliday, G. M., Kiernan, M. C., Mazumder, S., Timmins, H. C., Zoing, M., Pamphlett, R., … Williams, K. L. (2023). Short tandem repeat expansions in sporadic amyotrophic lateral sclerosis and frontotemporal dementia. https://www.science.org

7.   Lattante, S., Pomponi, M. G., Conte, A., Marangi, G., Bisogni, G., Patanella, A. K., Meleo, E., Lunetta, C., Riva, N., Mosca, L., Carrera, P., Bee, M., Zollino, M., & Sabatelli, M. (2018). ATXN1 intermediate-length polyglutamine expansions are associated with amyotrophic lateral sclerosis. Neurobiology of Aging, 64, 157.e1-157.e5. https://doi.org/10.1016/j.neurobiolaging.2017.11.011

8.   Elden, A. C., Kim, H. J., Hart, M. P., Chen-Plotkin, A. S., Johnson, B. S., Fang, X., Armakola, M., Geser, F., Greene, R., Lu, M. M., Padmanabhan, A., Clay-Falcone, D., McCluskey, L., Elman, L., Juhr, D., Gruber, P. J., Rüb, U., Auburger, G., Trojanowski, J. Q., … Gitler, A. D. (2010). Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature, 466(7310), 1069–1075. https://doi.org/10.1038/nature09320

9.   Figueroa, K. P., Gross, C., Buena-Atienza, E., Paul, S., Gandelman, M., Kakar, N., Sturm, M., Casadei, N., Admard, J., Park, J., Zühlke, C., Hellenbroich, Y., Pozojevic, J., Balachandran, S., Händler, K., Zittel, S., Timmann, D., Erdlenbruch, F., Herrmann, L., … Pulst, S. M. (2024). A GGC-repeat expansion in ZFHX3 encoding polyglycine causes spinocerebellar ataxia type 4 and impairs autophagy. In Nature Genetics (Vol. 56, Issue 6, pp. 1080–1089). Nature Research. https://doi.org/10.1038/s41588-024-01719-5

10.   Paucar, M., Nilsson, D., Engvall, M., Laffita-Mesa, J., Söderhäll, C., Skorpil, M., Halldin, C., Fazio, P., Lagerstedt-Robinson, K., Solders, G., Angeria, M., Varrone, A., Risling, M., Jiao, H., Nennesmo, I., Wedell, A., & Svenningsson, P. (2024). Spinocerebellar ataxia type 4 is caused by a GGC expansion in the ZFHX3 gene and is associated with prominent dysautonomia and motor neuron signs. Journal of Internal Medicine, 296(3), 234–248. https://doi.org/10.1111/joim.13815

11.   Wallenius, J., Kafantari, E., Jhaveri, E., Gorcenco, S., Ameur, A., Karremo, C., Dobloug, S., Karrman, K., de Koning, T., Ilinca, A., Landqvist Waldö, M., Arvidsson, A., Persson, S., Englund, E., Ehrencrona, H., & Puschmann, A. (2024). Exonic trinucleotide repeat expansions in ZFHX3 cause spinocerebellar ataxia type 4: A poly-glycine disease. American Journal of Human Genetics, 111(1), 82–95. https://doi.org/10.1016/j.ajhg.2023.11.008

12.   Pérez Baca, M. del R., Jacobs, E. Z., Vantomme, L., Leblanc, P., Bogaert, E., Dheedene, A., de Cock, L., Haghshenas, S., Foroutan, A., Levy, M. A., Kerkhof, J., McConkey, H., Chen, C. A., Batzir, N. A., Wang, X., Palomares, M., Carels, M., Agrawal, P., Armstrong Scott, D., … Callewaert, B. (2024). Haploinsufficiency of ZFHX3, encoding a key player in neuronal development, causes syndromic intellectual disability. American Journal of Human Genetics, 111(3), 509–528. https://doi.org/10.1016/j.ajhg.2024.01.013

13.   Rajan-Babu, I. S., Dolzhenko, E., Eberle, M. A., & Friedman, J. M. (2024). Sequence composition changes in short tandem repeats: heterogeneity, detection, mechanisms and clinical implications. In Nature Reviews Genetics (Vol. 25, Issue 7, pp. 476–499). Nature Research. https://doi.org/10.1038/s41576-024-00696-z

14.   Wright, G. E. B., Findlay Black Bsc, H., Collins Ba, J. A., Caron, N. S., Mbchb, H., Gall-Duncan Bsc, T., Pearson, C. E., Hayden, M. R., Wright, G. E. B., Black, H. F., Collins, J. A., Gall-Duncan, T., Caron, N. S., & Pearson, C. E. (2020). Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies. In Rapid Review Lancet Neurol (Vol. 19). www.thelancet.com/neurology

15.   Aston, A. N., & Dion, V. (2025). Interruptions impact clinical features of repeat expansion diseases, but how are they gained and lost? Trends in Genetics, 41(12), 1056–1067. https://doi.org/10.1016/j.tig.2025.07.005

16.   Huang, X. R., Tang, B. S., Jin, P., & Guo, J. F. (2022). The Phenotypes and Mechanisms of NOTCH2NLC-Related GGC Repeat Expansion Disorders: a Comprehensive Review. In Molecular Neurobiology (Vol. 59, Issue 1, pp. 523–534). Springer. https://doi.org/10.1007/s12035-021-02616-2

17.   Wang, L., Milton, M., Fearnley, L. G., Bhalala, O. G., Bahlo, M., & Rafehi, H. (2025). Identification of expanded and interrupted ATXN2 repeat expansions in Parkinson's disease and Lewy Body Dementia cohorts. Npj Parkinson's Disease, 11(1). https://doi.org/10.1038/s41531-025-01188-5

18.   Wu, S. S. L., McCann, E. P., Chan Moi Fat, S., Grima, N., Henden, L., Fearnley, L. G., Chiu, P., Williams, K. L., Rowe, D. B., Nicholson, G. A., Kiernan, M. C., Blair, I. P., Yang, S., & Fifita, J. A. (2026). Genetic characterisation of ATXN2 in Australian amyotrophic lateral sclerosis. Brain Disorders, 21. https://doi.org/10.1016/j.dscb.2025.100301

19.   Kozlowski, P., Sobczak, K., & Krzyzosiak, W. J. (2010). Genomic repeats and human diseases. http://genomemedicine.com/content/2/4/29

20.   Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000). El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis, 1(5), 293–299. https://doi.org/10.1080/146608200300079536

21.   van Rheenen, W., Pulit, S. L., Dekker, A. M., al Khleifat, A., Brands, W. J., Iacoangeli, A., Kenna, K. P., Kavak, E., Kooyman, M., McLaughlin, R. L., Middelkoop, B., Moisse, M., Schellevis, R. D., Shatunov, A., Sproviero, W., Tazelaar, G. H. P., van der Spek, R. A. A., van Doormaal, P. T. C., van Eijk, K. R., … Veldink, J. H. (2018). Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. European Journal of Human Genetics, 26(10), 1537–1546. https://doi.org/10.1038/s41431-018-0177-4

22.   The International HapMap Project The International HapMap Consortium*. (2003). http://www.hapmap.

23.   Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., & Sham, P. C. (2007). PLINK: A tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics, 81(3), 559–575. https://doi.org/10.1086/519795

24.   Dolzhenko, E., Deshpande, V., Schlesinger, F., Krusche, P., Petrovski, R., Chen, S., Emig-Agius, D., Gross, A., Narzisi, G., Bowman, B., Scheffler, K., van Vugt, J. J. F. A., French, C., Sanchis-Juan, A., Ibáñez, K., Tucci, A., Lajoie, B. R., Veldink, J. H., Raymond, F. L., … Birol, I.

(2019). ExpansionHunter: A sequence-graph-based tool to analyze variation in short tandem repeat regions. Bioinformatics, 35(22), 4754–4756. https://doi.org/10.1093/bioinformatics/btz431

25.   Mousavi, N., Margoliash, J., Pusarla, N., Saini, S., Yanicky, R., & Gymrek, M. (2021). TRTools: A toolkit for genome-wide analysis of tandem repeats. Bioinformatics, 37(5), 731–733. https://doi.org/10.1093/bioinformatics/btaa736

26.   Weisburd, B., Tiao, G., & Rehm, H. L. (2023). Insights from a genome-wide truth set of tandem repeat variation. https://doi.org/10.1101/2023.05.05.539588

27.   Jam, H. Z., Li, Y., DeVito, R., Mousavi, N., Ma, N., Lujumba, I., Adam, Y., Maksimov, M., Huang, B., Dolzhenko, E., Qiu, Y., Kakembo, F. E., Joseph, H., Onyido, B., Adeyemi, J., Bakhtiari, M., Park, J., Javadzadeh, S., Jjingo, D., … Gymrek, M. (2023). A deep population reference panel of tandem repeat variation. https://doi.org/10.1101/2023.03.09.531600

28.   Dolzhenko, E., Weisburd, B., Ibañez, K., Rajan-Babu, I. S., Anyansi, C., Bennett, M. F., Billingsley, K., Carroll, A., Clamons, S., Danzi, M. C., Deshpande, V., Ding, J., Fazal, S., Halman, A., Jadhav, B., Qiu, Y., Richmond, P. A., Saunders, C. T., Scheffler, K., … Eberle, M. A. (2022). REViewer: haplotype-resolved visualization of read alignments in and around tandem repeats. Genome Medicine, 14(1). https://doi.org/10.1186/s13073-022-01085-z

29.   Thiele, C., & Hirschfeld, G. (2021). Cutpointr: Improved estimation and validation of optimal cutpoints in r. Journal of Statistical Software, 98. https://doi.org/10.18637/jss.v098.i11

30.   Gianferrari, G., Martinelli, I., Zucchi, E., Simonini, C., Fini, N., Vinceti, M., Ferro, S., Gessani, A., Canali, E., Valzania, F., Sette, E., Pugliatti, M., Tugnoli, V., Zinno, L., Stano, S., Santangelo, M., de Pasqua, S., Terlizzi, E., Guidetti, D., … Mandrioli, J. (2022). Epidemiological, Clinical and Genetic Features of ALS in the Last Decade: A Prospective Population-Based Study in the Emilia Romagna Region of Italy. Biomedicines, 10(4). https://doi.org/10.3390/biomedicines10040819

31.   Nolin, S. L., Glicksman, A., Ersalesi, N., Dobkin, C., Brown, W. T., Cao, R., Blatt, E., Sah, S., Latham, G. J., & Hadd, A. G. (2015). Fragile X full mutation expansions are inhibited by one or more AGG interruptions in premutation carriers. Genetics in Medicine, 17(5), 358–364. https://doi.org/10.1038/gim.2014.106

32.   Menon, R. P., Nethisinghe, S., Faggiano, S., Vannocci, T., Rezaei, H., Pemble, S., Sweeney, M. G., Wood, N. W., Davis, M. B., Pastore, A., & Giunti, P. (2013). The Role of Interruptions in polyQ in the Pathology of SCA1. PLoS Genetics, 9(7). https://doi.org/10.1371/journal.pgen.1003648

33.   Mitina, A., Engchuan, W., Trost, B., Pellecchia, G., Scherer, S. W., & Yuen, R. K. C. (2025). Diverse short tandem repeat sequences influence gene regulation in human populations. Genome Biology, 26(1). https://doi.org/10.1186/s13059-025-03754-9

34.   Matuszek, Z., Arbab, M., Kesavan, M., Hsu, A., Roy, J. C. L., Zhao, J., Yu, T., Weisburd, B., Newby, G. A., Doherty, N. J., Wu, M., Shibata, S., Cristian, A., Tao, Y. A., Fearnley, L. G., Bahlo, M., Rehm, H. L., Xie, J., Gao, G., … Liu, D. R. (2025). Base editing of trinucleotide repeats that cause Huntington's disease and Friedreich's ataxia reduces somatic repeat expansions in patient cells and in mice. Nature Genetics, 57(6), 1437–1451. https://doi.org/10.1038/s41588-025-02172-8

35.   Wei, Q., Zhou, Q., Chen, Y., Ou, R., Cao, B., Xu, Y., Yang, J., & Shang, H. F. (2017). Analysis of SOD1 mutations in a Chinese population with amyotrophic lateral sclerosis: A case-control study and literature review. Scientific Reports, 7. https://doi.org/10.1038/srep44606

36.   Edgar, S., Ellis, M., Abdul-Aziz, N. A., Goh, K. J., Shahrizaila, N., Kennerson, M. L., & Ahmad-Annuar, A. (2021). Mutation analysis of SOD1, C9orf72, TARDBP and FUS genes in ethnically-diverse Malaysian patients with amyotrophic lateral sclerosis (ALS). Neurobiology of Aging, 108, 200–206. https://doi.org/10.1016/j.neurobiolaging.2021.07.008

37.   Chen, Z., Gustavsson, E. K., Macpherson, H., Anderson, C., Clarkson, C., Rocca, C., Self, E., Alvarez Jerez, P., Scardamaglia, A., Pellerin, D., Montgomery, K., Lee, J., Gagliardi, D., Luo, H., Hardy, J., Polke, J., Singleton, A. B., Blauwendraat, C., Mathews, K. D., … Ptáček, L. J. (2024). Adaptive Long-Read Sequencing Reveals GGC Repeat Expansion in ZFHX3 Associated with Spinocerebellar Ataxia Type 4. Movement Disorders, 39(3), 486–497. https://doi.org/10.1002/mds.29704